| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_52f14ac74eacfb038a07853e1084ab59 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1274
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-107 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-095 |
| filingDate |
2005-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba6f7148db9251f52be6f9d838b88808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4aacfc95dee5513d6fdf0ff8aaba57a2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9d8df60bb5742cdfce35293c4574b9c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78f109759fc8a280add073d0a772ad06 |
| publicationDate |
2007-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20070104599-A |
| titleOfInvention |
Somatostatin-like formulation |
| abstract |
The present invention provides a composition comprising a) at least one diacyl glycerol; b) at least one phosphatidyl choline; c) at least one oxygen containing organic solvent; d) relating to an initial formulation of a low viscosity mixture comprising at least one somatostatin analog, wherein the initial formulation can form or form at least one liquid crystal phase in contact with an aqueous fluid. Such formulations are useful for creating depot compositions for controlled release of somatostatin analogs such as octreotide. Also provided are methods of treatment comprising administration of such formulations, such as prefilled administration devices and kits comprising the formulations. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20160030232-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20150016977-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20140111661-A |
| priorityDate |
2005-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |